Skip to content
Est. 1998 proudly celebrating 27 years of standing behind American companies
American Origin Unverified This profile is unclaimed and has not been independently reviewed. Claim & get verified

Immunome Inc. (IMNM)

$17.99 -1.48% NASDAQ: IMNM · 15-min delayed
  • BOTHELL, Washington
  • Public · NASDAQ: IMNM
  • 177 employees
$2.5BMarket cap
$6.9MRevenue · FY2025
-$212.4MNet income
177Employees
IMNMNASDAQ
2020IPO

About Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

This profile is unclaimed. An authorized representative can claim it free to control the page and activate the embeddable Verified badge.

Reported figures

Financial summary

Revenue FY2025
$6.9M
Net income
-$212.4M
Total assets
$683.2M
Market cap
$2.5B

Source: SEC EDGAR · updated Jun 7, 2026

NASDAQ: IMNM
$17.99 -1.48%

15-minute delayed · data by Polygon.io

Past year · hover for prices

$9.77 $29.82

52-week range

Market cap
$2.5B
Shares outstanding
139.8M
Open
—
Day range
–
Prev close
—
Volume
—
IPO date
Oct 2, 2020

Immunome Inc. (IMNM) Stock Price

  • Reported a net loss of $212.4M in FY2025.
  • Trading 40% below its 52-week high.

Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.

No reviews yet. Be the first to review Immunome Inc..

Write a review
Newsroom

News about Immunome Inc.

News & sentiment via Polygon.io

FAQ

Immunome Inc.: frequently asked questions

Is Immunome Inc. an American company?

Immunome Inc. is a US-based company headquartered in Bothell, Washington, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.

Where is Immunome Inc. headquartered?

Immunome Inc. is headquartered in Bothell, Washington, United States.

Is Immunome Inc. publicly traded?

Yes — Immunome Inc. is a publicly traded company. Its stock trades under the ticker symbol IMNM on the NASDAQ.

What does Immunome Inc. do?

Immunome Inc. is an American Pharmaceuticals company in the Health & Beauty sector.

Explore

Similar companies

Browse all →